Serum Her2 extracellular domain (ECD) levels, pAkt and pMAPK expressions as potential markers for response to trastuzumab(T)-based therapy in metastatic breast cancer (MBC) patients (PTS). A Turkish oncology group study - (:unkn) unknown (OXFORD UNIV PRESS, 2006)